Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Christine Lydon"'
Autor:
Mark Awad, Mizuki Nishino, Mariano Severgnini, Biagio Ricciuti, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Greg Jones, Tim Forshew, Christine Lydon, Michael Cheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Currently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for patients with advanced non-small cell lung cancer (NSCLC). Having an early pharmacodynamic marker
Externí odkaz:
https://doaj.org/article/e6145a4c40b5449aabb45da655be4ef6
Autor:
Mark Awad, Mizuki Nishino, Mariano Severgnini, Biagio Ricciuti, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Greg Jones, Tim Forshew, Christine Lydon, Michael Cheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/66aac74d6715476bb41128518795d259
Autor:
David A. Barbie, Kwok-Kin Wong, Glenn Dranoff, Scott J. Rodig, F. Stephen Hodi, Levi A. Garraway, Peter S. Hammerman, Neal Lindeman, Gad Getz, Pasi Janne, Geoffrey Oxnard, Scott L. Carter, Lynette Sholl, Joshua Helmkamp, Alexandra R. Rabin, Joshua A. Wong, Ada G. Avila, Stacy Mach, Christine Lydon, Tran Thai, Aaron Chevalier, Vanesa Rojas-Rudilla, Maegan Harden, Marios Giannakis, Amaro Taylor-Weiner, Karrie Wong, Shohei Koyama, Yan Liu, Hadrien G. Golay, Eliezer M. Van Allen
Table S1: All somatic mutations and short insertion/deletions. This table provides information on all somatic point mutations and short insertion/deletions observed in the tumor sample from this patient. Additional annotations about protein change, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d4ce4616ac770ac4c4356dd982aad46
https://doi.org/10.1158/2326-6066.22537807
https://doi.org/10.1158/2326-6066.22537807
Autor:
David A. Barbie, Kwok-Kin Wong, Glenn Dranoff, Scott J. Rodig, F. Stephen Hodi, Levi A. Garraway, Peter S. Hammerman, Neal Lindeman, Gad Getz, Pasi Janne, Geoffrey Oxnard, Scott L. Carter, Lynette Sholl, Joshua Helmkamp, Alexandra R. Rabin, Joshua A. Wong, Ada G. Avila, Stacy Mach, Christine Lydon, Tran Thai, Aaron Chevalier, Vanesa Rojas-Rudilla, Maegan Harden, Marios Giannakis, Amaro Taylor-Weiner, Karrie Wong, Shohei Koyama, Yan Liu, Hadrien G. Golay, Eliezer M. Van Allen
Figure S1: Orthogonal sequencing of JAK3 mutations. Figure S2: Copy number profile of tumor. Figure S3: Absolute copy number. Figure S4: PHIAL gel of patient's somatic exome results. Figure S5. Modified H-scores for tumor and immune cells. Figure S6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2013d15a1671e5cc0f9e54c8e10f7f53
https://doi.org/10.1158/2326-6066.22537810.v1
https://doi.org/10.1158/2326-6066.22537810.v1
Autor:
David A. Barbie, Kwok-Kin Wong, Glenn Dranoff, Scott J. Rodig, F. Stephen Hodi, Levi A. Garraway, Peter S. Hammerman, Neal Lindeman, Gad Getz, Pasi Janne, Geoffrey Oxnard, Scott L. Carter, Lynette Sholl, Joshua Helmkamp, Alexandra R. Rabin, Joshua A. Wong, Ada G. Avila, Stacy Mach, Christine Lydon, Tran Thai, Aaron Chevalier, Vanesa Rojas-Rudilla, Maegan Harden, Marios Giannakis, Amaro Taylor-Weiner, Karrie Wong, Shohei Koyama, Yan Liu, Hadrien G. Golay, Eliezer M. Van Allen
PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. We performed comprehensive gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4da3421381f2d68bb453c4ab2068000
https://doi.org/10.1158/2326-6066.c.6548557.v1
https://doi.org/10.1158/2326-6066.c.6548557.v1
Autor:
Mark M. Awad, Alice T. Shaw, Jochen K. Lennerz, Bruce E. Johnson, A. John Iafrate, Nicholas A. Jessop, Tom Nguyen, Christine Lydon, Lorin A. Ferris, Chiara Ambrogio, Beow Y. Yeap, Pablo Martinez, Ibiayi Dagogo-Jack
Overlap between BRAF and NF1 Genetic Alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab17b7110ba984f7a31260c71f5839a
https://doi.org/10.1158/1078-0432.22475919.v1
https://doi.org/10.1158/1078-0432.22475919.v1
Autor:
Pasi A. Jänne, David M. Jackman, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Christine Lydon, Mohit Butaney, Jason L. Hornick, Ashley K. Pelton, Scott J. Rodig, Lynette M. Sholl, Antonio Calles
Supplementary Table S3. List of LKB1 mutant lung adenocarcinoma specimens by OncoMap tested for LKB1 IHC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64be48162a7f58206a7c5cf8d42cf5e0
https://doi.org/10.1158/1078-0432.22461318
https://doi.org/10.1158/1078-0432.22461318
Autor:
Pasi A. Jänne, David M. Jackman, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Christine Lydon, Mohit Butaney, Jason L. Hornick, Ashley K. Pelton, Scott J. Rodig, Lynette M. Sholl, Antonio Calles
Supplementary Table S1. KRAS mutant NSCLC patients' characteristics (n=514)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9593843abdbc2031eb9bea45a3b8cb8d
https://doi.org/10.1158/1078-0432.22461324
https://doi.org/10.1158/1078-0432.22461324
Autor:
Pasi A. Jänne, David M. Jackman, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Christine Lydon, Mohit Butaney, Jason L. Hornick, Ashley K. Pelton, Scott J. Rodig, Lynette M. Sholl, Antonio Calles
Supplemental Figure 2. A, KRAS G12C mutation is the most frequently mutated in smokers while G12D is most common in never-smokers. B and C, Never-smokers were significantly more likely than former or current smokers to have a transition mutation (G>A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e3f79c852edc3b4f79ef8a65b92632
https://doi.org/10.1158/1078-0432.22461309
https://doi.org/10.1158/1078-0432.22461309
Autor:
Pasi A. Jänne, Bruce E. Johnson, Lynette M. Sholl, Beow Y. Yeap, Christine Lydon, Jeanne Shen, Mohit Butaney, Mizuki Nishino, Atsuko Ogino, Stephanie Cardarella
Purpose:BRAF mutations are found in a subset of non–small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations.Experimental Design: Using DNA sequencing, we succe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71587e8112d7c832faccd5f29660f093
https://doi.org/10.1158/1078-0432.c.6521069.v1
https://doi.org/10.1158/1078-0432.c.6521069.v1